Comparison of Effects of Oxycodone and Sufentanil on Cardiovascular Stress Induced by Tracheal Intubation in the Patients With Coronary Heart Disease Undergoing Major Noncardiac Surgery

Overview

To evaluate the effect of oxycodone and sufentanil in preventing cardiovascular responses to tracheal intubation in the patients with coronary heart disease (CHD).

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Other
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: August 31, 2019

Detailed Description

Laryngoscopy and tracheal intubation can provoke an increase of blood pressure (BP) and/or HR [1.2]. This hemodynamic stress may lead to an imbalance between myocardial oxygen consumption and supply and therefore induce myocardial ischemia, which may be endurable in the patients with normal cardiovascular condition but is potential harmful to the patients with coronary heart disease. Thus it is critical to attenuate the cardiovascular stress induced by laryngoscopy and endotracheal intubation in the high risk patients.

Interventions

  • Drug: Oxycodone 10mg
    • induction with 0.3mg/kg of oxycodone in general anesthesia
  • Drug: Sufentanil
    • induction with 0.3 µg/kg of Sufentanil in general anesthesia

Arms, Groups and Cohorts

  • Experimental: Oxycodone group
  • Experimental: Sufentanil group

Clinical Trial Outcome Measures

Primary Measures

  • blood pressure(SBP)、diastolic blood pressure(DBP)、mean arterial pressure(MAP)
    • Time Frame: one second before anesthesia induction, the moment when tracheal catheter passes through glottis and at 1, 3, 5 min after tracheal intubation
    • Under local anesthesia invasive artery line was put to the patients to monitor systolic blood pressure(SBP)、diastolic blood pressure(DBP)、mean arterial pressure(MAP)

Participating in This Clinical Trial

Inclusion Criteria

The coronary angiography from each patient showed that lesions exist in at least one main coronary artery

Exclusion Criteria

a history of reactive airway disease, gastroesophageal reflux, morbid obesity, a known or predicted difficult airway

Gender Eligibility: Female

Minimum Age: 60 Years

Maximum Age: 85 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Shengjing Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Yanchao Yang, Principal Investigator – Shengjing Hospital
  • Overall Official(s)
    • Junchao Zhu, Study Director, Shengjing Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.